english.prescrire.org > Prescrire International > N°132 - November 2012

n°132

November 2012

Issue Contents
Editorial

Free  Margins

p.256
Beware non-inferiority trials

New Products


Rivaroxaban and atrial fibrillation (New Indication)

p.257-260
Continue to use warfarin or, in some cases, dabigatran

Acute coronary syndrome and rivaroxaban: not so fast...

p.260

Subcutaneous human hepatitis B immunoglobulin (New Drug)

p.261
Scant assessment after liver transplantation for hepatitis B

Rilpivirine (New Drug)

p.262-265
First-line treatment of HIV infection: efavirenz is better documented

INN common stem: -tinib

p.265

Adverse Effects


Bevacizumab: more fatal adverse effects

p.266-267
Hypertension, thrombosis, bleeding

Nicorandil: more cases of mucocutaneous ulceration

p.267
Prolonging marketing authorisation is unacceptable

Free  Orodispersible paracetamol tablets: danger of poisoning in children.

p.268
Keep products out of reach of children

Free  Orodispersible paracetamol: the packaging makes all the difference

p.268

Zinc oxide: artefacts on mammograms

p.269
Don't apply ointment before mammography

Tianeptine: hepatic, neurological and cutaneous adverse effects

p.269
Unacceptable adverse effect profile

Electrocautery and alcohol: risk of fire and burns

p.269
Allow alcohol-based antiseptics to dry

Single-dose packaging: common errors

p.269
Mostly intranasal and ocular

Reviews


Contacts of infectious tuberculosis patients

p.270-275
Monitor those at highest risk

Variable interpretation of the tuberculin skin test

p.272

Prescrire’s advice

p.274
Contacts of tuberculosis patients: watchful waiting or treatment in selected cases

Preventing recurrence after deep vein thrombosis

p.275
Treatment durations depending on the context

Outlook


Treatment goals: discuss them with the patient

p.276-278
Before assessing benefits and harms

A few questions to clarify the goals of treatment

p.277

Free  European Medicines Agency: riddled with conflicts of interest

p.278
Prevention of drug disaster is at stake

Naming drug substances at the national level

p.279
Mainly in the United Kingdom and the United States

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe